Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Gastric04 in HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma
MOH_2021-07-21_010148Phase 3Recruiting
- Sponsor
- Daiichi Sankyo, Inc
- Start
- May 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab deruxtecan in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Daiichi Sankyo, Inc. Primary endpoint: Overall survival. Started May 2021; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on MOH_2021-07-21_010148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-07-21_010148.